You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)將在2024 ASCO年會上公佈CS5001(ROR1 ADC)I期研究數據
格隆匯 05-06 12:16

格隆匯5月6日丨基石藥業-B(02616.HK)宣佈,公司研發管綫2.0的重磅產品CS5001(ROR1 ADC)最新研究數據將在2024年美國臨牀腫瘤學會(ASCO)年會上以壁報形式展示。本屆ASCO年會將於2024年5月31日至6月4日在美國芝加哥舉行。

詳細信息如下:

題目: 新型ROR1抗體偶聯藥物CS5001治療晚期實體瘤和淋巴瘤患者的1a/b期全球多中心首次人體研究

壁報展示時間: 2024年6月1日,上午9:00-12:00(美國中部夏令時)

摘要發表編號:3023

據悉,CS5001是一款臨牀階段以受體酪氨酸激酶樣孤兒受體1(receptor tyrosine kinase-like orphanreceptor 1, ROR1)為靶點的抗體偶聯藥物(ADC)。CS5001具有獨特的設計,使用腫瘤特異激活的吡咯並苯二氮卓(pyrrolobenzodiazepine, PBD)前毒素載荷(Payload)和連接子(linker)。CS5001只在到達腫瘤,且被腫瘤細胞內吞後,在溶酶體中其連接子才被在腫瘤細胞中高表達的特異性酶切割,進而釋放PBD前毒素,繼而PBD前毒素在腫瘤細胞內被激活,從而殺死腫瘤細胞。這種連接子加前毒素的"雙控"機制有效地減少與傳統PBD載荷有關的毒性問題,而獲得更大的安全窗口。CS5001已在幾種臨牀前癌症模型中證明具有完全的腫瘤抑制作用,並展示出良好的血清半衰期及藥代動力學特徵。這些都將會轉化為多種實體和血液惡性腫瘤的廣泛治療指標。此外,CS5001利用定向偶聯技術獲得精準的藥物抗體比率(DAR),便於實現均質生產及大規模生產。

2020年10月,基石藥業與LegoChem Biosciences, Inc.(LCB)就CS5001的開發和商業化達成授權協定。CS5001最初是由韓國領先的生物科技公司LCB和ABL Bio共同合成。根據協定條款,基石藥業獲得CS5001在韓國以外的全球其他地區的獨家開發和商業化權利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account